Karen Whitehead
Adult Health · Washington, NCNPI 1295037299
Payments from drug & device makers
Across 102 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$497
- GSK$351
- Lilly USA, LLC$303
- Amgen$259
- Novo Nordisk$182
- Mylan Specialty L.p.$162
- plus $614 from 13 others
What the payments were for
- Food & beverage$2,34999%
- Other$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $497 |
| GSK | 19 | $351 |
| Lilly USA, LLC | 13 | $303 |
| Amgen | 9 | $259 |
| Novo Nordisk | 12 | $182 |
| Mylan Specialty L.p. | 5 | $162 |
| Abbott | 6 | $128 |
| Pfizer | 6 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| AbbVie | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Dexcom, Inc. | 2 | $37 |
| Exact Sciences | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Indivior Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$139
- TRELEGY ELLIPTA$125
- BREZTRI$124
- Yupelri$123
- FARXIGA$120
How this compares
$2,369 in reported general payments places this provider in the 80th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $111,313 |
| EliquisApixaban | 113 | $78,833 |
| JanuviaSitagliptin Phosphate | 72 | $67,914 |
| MounjaroTirzepatide | 46 | $58,791 |
| TrulicityDulaglutide | 58 | $58,033 |
| JardianceEmpagliflozin | 52 | $53,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $28,993 |
| XareltoRivaroxaban | 32 | $26,643 |
| MyrbetriqMirabegron | 20 | $17,657 |
| LinzessLinaclotide | 23 | $16,468 |
| Repatha SureclickEvolocumab | 16 | $14,915 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $12,501 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,987 |
| BrilintaTicagrelor | 12 | $9,494 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $303 | $116,824104 claims |
| Novo NordiskOzempic | $182 | $111,313106 claims |
| PfizerEliquis | $98 | $78,833113 claims |
| Boehringer IngelheimJardiance | $19 | $53,15852 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $351 | $47,37785 claims |
| Johnson & JohnsonXarelto | $17 | $26,64332 claims |
| AbbVieLinzess, Synthroid | $49 | $19,56059 claims |
| AstraZenecaBrilinta, Symbicort | $497 | $12,23725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 adult health providers in North Carolina.
Other adult health in Washington
- Jolene SpencerWashington$83K
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.